Página 1 desde 33 resultados
FIELD OF INVENTION
The present invention relates to androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The agents are useful for a) male contraception; b) treatment of a variety of hormone-related
FIELD OF INVENTION
The present invention relates to androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The agents are useful for a) male contraception; b) treatment of a variety of hormone-related
FIELD OF INVENTION
The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new
FIELD OF INVENTION
The present invention relates to androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen receptor modulators
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen receptor
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which are selective androgen receptor modulators (SARM). The SARM compounds are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which are selective androgen receptor modulators (SARM). The SARM compounds are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen receptor
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen receptor
FIELD OF INVENTION
The present invention relates to a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds, which are selective androgen receptor
FIELD OF INVENTION
The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of
FIELD OF INVENTION
The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA), which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of
The present invention relates generally to phosphatidylinositol 3-kinase (PI3K) enzymes, and more particularly to selective inhibitors of PI3K activity and to methods of using such materials.
BACKGROUND OF THE INVENTION
Cell signaling via 3'-phosphorylated phosphoinositides has been implicated in a
BACKGROUND OF THE INVENTION
The present invention relates generally to phosphatidylinositol 3-kinase (PI3K) enzymes, and more particularly to selective inhibitors of PI3K activity and to methods of using such materials.
Cell signaling via 3'-phosphorylated phosphoinositides has been implicated in a
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a DNA that encodes the transcription factor BP1, a vector containing the DNA and a host cell containing the DNA. The invention also relates to an antisense DNA or RNA to the DNA encoding BP1, methods for treating